Achieve Life Sciences Business Summary

Achieve Life Sciences, Inc. (ACHV) is a late-stage clinical pharmaceutical company primarily focused on the development and commercialization of cytisinicline, a plant-based alkaloid designed to treat nicotine addiction. The company currently operates as a pre-revenue entity, with its business model centered on advancing its lead candidate through the FDA regulatory pipeline to secure market approval for smoking and e-cigarette cessation. Revenue generation is projected to stem from direct commercial sales in the U.S. and potential global licensing or strategic M&A transactions, supported by a $300 million shelf registration filed in early 2026. Achieve's primary business segments are categorized by indication: adult smoking cessation, which has a PDUFA action date of June 20, 2026, and nicotine e-cigarette cessation, which holds FDA Breakthrough Therapy designation. Within the competitive landscape, Achieve directly challenges established pharmacotherapies such as Pfizer’s Chantix (varenicline) and GSK’s Zyban (bupropion), positioning cytisinicline as a superior alternative due to its favorable safety profile and shorter treatment duration. Compared to biotech peers like Camp4 Therapeutics and Silence Therapeutics, Achieve is uniquely positioned as a single-asset specialist nearing a major commercial inflection point in the multi-billion dollar nicotine dependence market. The company is led by co-founder Richard (Rick) Stewart, who reassumed the role of President and CEO in August 2024 to steer the firm through its transition from clinical development to commercialization. Stewart brings extensive M&A and leadership experience from his previous tenure as CEO of Amarin and founder of Ricanto Limited. The executive suite was further strengthened by the appointment of Mark Oki as CFO in late 2024 and the promotion of Dr. Mark Rubinstein to permanent Chief Medical Officer in January 2026; Rubinstein is a renowned expert in nicotine addiction and Professor Emeritus at UCSF. Other key leaders include COO Craig Donnelly and CCO Jaime Xinos, both of whom possess over 25 years of industry experience. The Board of Directors is chaired by Thomas King, a veteran biopharma executive with a history of successful exits, and includes recent appointees Nancy Phelan and Dr. Kristen Slaoui, formerly of GSK. Notable institutional backing is provided by Franklin Resources, Propel Bio Management, and Dialectic Capital Management, reflecting significant investor confidence in the company’s late-stage clinical data.